• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description may have changed. Be sure to look at the supplements to get an up-to-date view of this device.
 
DeviceNUCLEUS HYBRID L24 IMPLANT SYSTEM
Classification Namehybrid cochlear implant
Generic Namehybrid cochlear implant
Applicant
Cochlear Americas
13059 east peakview avenue
centennial, CO 80111
PMA NumberP130016
Date Received06/03/2013
Decision Date03/20/2014
Product Code
PGQ[ Registered Establishments with PGQ ]
Docket Number 14M-0327
Notice Date 04/10/2014
Advisory Committee Ear Nose & Throat
Clinical Trials NCT00678899
Expedited Review Granted? Yes
Combination Product No
Approval Order Statement 
Approval for the nucleus® hybrid l24 cochlear implant system. The nucleus® hybrid l24 cochlear implant system is intended to provide electric stimulation to the mid-to-high frequency region of the cochlea and acoustic amplification to the low frequency regions, for patients with residual low frequency hearing sensitivity. The system is indicated for unilateral use in patients aged 18 years and older who have residuallow-frequency hearing sensitivity and severe to profound high frequency sensorineural hearing loss, and who obtain limited benefit from appropriately fit bilateral hearing aids. Typical preoperative hearing of candidates ranges from normal to moderate hearing loss in the low frequencies (thresholds no poorer than 60 db hl up to and including 500 hz), with severe to profound mid to high frequency hearing loss (threshold average of 2000, 3000, and 4000 hz >=75 db hl) in the ear to be implanted, and moderately severe to profound mid to high frequency hearing loss (threshold average of 2000, 3000, and 4000 hz >=60 db hl) in the contralateral ear. The cnc word recognition score will be between 10% and 60%, inclusively, in the ear to be implanted in the preoperative aided condition and in the contralateral ear will be equal to or better than that of the ear to be implanted but not more than 80% correct. Prospective candidates shouldgo through a suitable hearing aid trial, unless already appropriately fit with hearing aids.
Approval Order Approval Order
Summary Summary of Safety and Effectiveness
Labeling Labeling
Post-Approval StudyShow Report Schedule and Study Progress
Supplements: S001 S002 S003 S004 S005 S006 S007 S008 S009 
S010 S011 S012 S013 S014 S015 S017 S018 S020 
-
-